Category Ranking

98%

Total Visits

921

Avg Visit Duration

2 minutes

Citations

20

Article Abstract

Purpose: Patients with chronic obstructive pulmonary disease (COPD) frequently exhibit intestinal leaks and age-related muscle impairment, termed sarcopenia. The sarcopenia-related quality-of-life (SarQoL) is a tool to evaluate the quality of life of sarcopenic patients. However, the association of intestinal leak with SarQoL in COPD patients remains unknown.

Methods: We recruited male controls (n=87, age=72.7±6.7 years) and COPD patients (n=81, age=70.9±5.8 years) to validate the Pashto version of SarQoL. This was followed by an investigation of the sarcopenia indices, including handgrip strength (HGS), skeletal mass index (SMI), and gait speed. We also measured plasma zonulin (a marker of intestinal leak) and lipopolysaccharides binding protein (LBP) (a marker of bacterial load).

Results: We first confirmed the reliability of Pashto SarQoL by demonstrating its internal consistency, test-retest reliability, and absence of a floor-and-ceiling effect. Next, we report that COPD patients had higher plasma zonulin and LBP levels and lower SarQoL, HGS, SMI, and gait speed than controls (all p<0.05). Plasma zonulin demonstrated inverse correlations with SarQoL domains for locomotion, functionality, activities of daily living, and cumulative SarQoL scores in COPD patients (all p<0.05). Further, higher LBP levels were correlated with lower scores on SarQoL domains for physical and mental health, locomotion, functionality, fear, and cumulative SarQoL scores (all p<0.05).

Conclusion: In conclusion, intestinal leaks and associated bacterial load potentially contribute to reduced SarQoL in COPD patients. Future studies should investigate intestinal mucosal repair as a therapeutic option in COPD patients.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC12205755PMC
http://dx.doi.org/10.2147/COPD.S511562DOI Listing

Publication Analysis

Top Keywords

copd patients
12
quality life
8
patients chronic
8
chronic obstructive
8
obstructive pulmonary
8
pulmonary disease
8
intestinal leak
8
smi gait
8
gait speed
8
plasma zonulin
8

Similar Publications

β-blocker and clinical outcomes in patients after myocardial infarction: a systematic review and meta-analysis.

Eur J Clin Pharmacol

September 2025

Department of Forensic Pathology, West China School of Basic Medical Sciences & Forensic Medicine, Sichuan University, Chengdu, 610041, China.

Background And Objective: While current clinical guidelines generally advocate for beta-blocker therapy following acute myocardial infarction (AMI), conflicting findings have surfaced through large-scale observational studies and meta-analyses. We conducted this systematic review and meta-analysis of published observational studies to quantify the long-term therapeutic impact of beta-blocker across heterogeneous AMI populations.

Methods: We conducted comprehensive searches of the PubMed, Embase, Cochrane, and Web of Science databases for articles published from 2000 to 2025 that examine the link between beta-blocker therapy and clinical outcomes (last search update: March 1, 2025).

View Article and Find Full Text PDF

Uncovering a novel role of nAChRs in oxidative stress-mediated vascular dysfunction in COPD.

Redox Biol

August 2025

Department of Medicine, School of Medicine, Universidad Autónoma de Madrid, Madrid, Spain; Instituto Investigación Sanitaria-Princesa IIS-IP, Madrid, Spain; Centro de Investigación Biomédica en Red de Enfermedades Respiratorias (CIBERES), Instituto de Salud Carlos III, Madrid, Spain. Electronic

Tobacco smoke is the main risk factor for the development of chronic obstructive pulmonary disease (COPD). Despite current therapies alleviate symptoms there are limitations in the efficacy of treatments to curb its cardiovascular morbidities, particularly vascular dysfunction and the development of pulmonary hypertension. Our previous studies demonstrate that cigarette smoke directly contributes to pulmonary arterial dysfunction.

View Article and Find Full Text PDF

Evaluation and management of hemoptysis.

JAAPA

September 2025

Clay W. Walker is an assistant professor of family medicine at Mayo Clinic in Phoenix, AZ; director of didactic education and an assistant professor in the PA program at A.T. Still University in Mesa, AZ; and an adjunct assistant professor at Rush University in Chicago, IL. Thomas Hartman is directo

Hemoptysis, defined as the expectoration of blood originating from the lower respiratory tract, is a clinical symptom with a wide differential diagnosis that ranges from benign to life-threatening causes. Common causes vary by geographic region and care setting, with respiratory infections, malignancy, bronchiectasis, and chronic obstructive pulmonary disease being predominant in resource-rich countries and tuberculosis remaining the leading cause in resource-limited areas. Though most cases are mild and self-limited, hemoptysis can be a life-threatening medical emergency; these cases are associated with a mortality exceeding 50%, primarily due to asphyxia.

View Article and Find Full Text PDF

Purpose: Non-adherence to inhaled medication poses a significant clinical and economic burden on patients with respiratory diseases. This narrative review provides an overview of key aspects of hair analysis, in general and specific for inhaled medications, and explores the potential of hair analysis as a novel tool to monitor adherence to inhaled medications.

Methods: PubMed searches were conducted to explore four aspects: (1) mechanisms of (inhaled) drug's systemic absorption and deposition in hair; (2) quantification of drugs in hair; (3) factors impacting (inhaled) drug hair concentrations; and (4) clinical studies assessing inhaled medication adherence through hair analysis.

View Article and Find Full Text PDF

Background: Comorbidities may affect incidence and management of cancers. The burden of comorbidities among AIAN cancer patients and survivors is unknown.

Methods: Using SEER-Medicare, we identified AIAN people aged 66+ years diagnosed with female breast, lung, and colorectal cancers (2000-2019), with at least one year of Medicare coverage prior to diagnosis.

View Article and Find Full Text PDF